Omics · Nov 16, 2026
CKMT2 Marks a Mitochondrial and Oxidative-Fiber Program in Sarcopenic Human Skeletal Muscle: An Integrative Four-Cohort Transcriptomic and Single-Nucleus Analysis
By Qi L, Li Y, Wang X et al.
Sarcopenia is a heterogeneous skeletal-muscle disease in which mitochondrial bioenergetic decline is recurrent. In a discovery transcriptome (GSE226151) screened by differential expression and monotonic trend within a candidate space annotated with database-derived nicotine targets, five algorithms converged on one gene, CKMT2. Across four human vastus lateralis cohorts (268 donors; three independent of discovery), CKMT2 was lower in cases (pooled Hedges’ g = −0.60, p = 0.006), and between-cohort heterogeneity was explained entirely by case definition: the deficit was large and consistent in sarcopenia-defined cohorts ( g = −1.01) but small and nonsignificant in frailty-defined cohorts ( g = −0.27; between-subgroup p = 0.008). Its discrimination did not survive adjustment for mitochondrial content and fiber-type composition (area under the curve [AUC]: 0.77–0.49), its effect size lay at the median of 76 oxidative-phosphorylation subunits, and it was unchanged by 6 months of resistance training in 72 donors with paired biopsies. At protein-level CKMT2 was 31% lower in sarcopenic than healthy older muscle, while cytosolic CKM and CKB were unchanged. Single-nucleus analysis linked lower CKMT2 to reduced oxidative phosphorylation and attenuated contractile programs. CKMT2 marks a coordinated mitochondrial and oxidative-fiber program rather than an independent biomarker. All analyses are computational; no experimental validation was performed.